All BD patients had failed after anti-TNF agents and 10/11 after at least two anti-TNF agents sequentially used at least for 6 months (typically adalimumab subcutaneously 40 mg weekly or fortnightly or infliximab intravenous at 5 mg/kg every 4 weeks for 4 doses and then every 6 weeks or etanercept SC at 50 mg twice a week) with or without other immunomodulatory agents. This evidence concerns the gene TNF and Behcet disease.